Pharmaceutical Industry in South Africa: Market Research Reports, Statistics and Analysis

Company Report: Pathology In South Africa For Year 2012

... Since 2010. 4. The gains also highlight the enormous efforts that are still needed to overcome south africa S hiv and tb epidemics. Due to the lifesaving benefits of treatment, the total number ...

Company Report: Pathology In The United States And Africa For Yea ...

Company Report: Pharmaceutical For Year 2013

... As well as for ship propulsion systems, is a group division of voith gmbh. Voith sets standards in the markets energy, oil & gas, paper, raw materials and transportation & automotive. Founded in 1867 ...

Company Report: Pathology In Africa For Year 2012

... This provisional pdf corresponds to the article as it appeared upon acceptance. Fully formatted pdf and full text (html) versions will be made available soon. Efficient and equitable hiv prevention ...

Company Report: Vaccine In Africa For Year 2013

... vaccines) Reserve: rolling stock Bank: bulk and/or ready to use : to ensure product availability and rapid response in case of threat of outbreaks vaccines against diseases that can have ...

Vitamin Market In The United States And South Africa

... Review december 2012. Photo from istockphoto.Com results of insufficient folic acid (vitamin b9) Children born with neural tube birth defects (ntds) such as spina bifida Permanently disabling ...

Pharmaceutical Market In South Africa

... A whole Mortality rates in sub-saharan africa spiralled out of control in the 1990s due to rapidly escalating hiv and aids epidemic In south africa, the rate started to decrease when we started ...

Drug Sector In Africa

... Equity of access on paper but weak 1010 20/04/2013 harm reduction as a policy pillar is: Rejected by nigeria; Included in 2012-16 drug master plan of so africa but defined as achieved through treatment ...

The South African Clinical Trial Market : Innovation And Technolo ...

... For the individual patient who participated in a clinical trial continued access to the product that has been identified as beneficial is crucial. It is recognized; however, that post trial access of patients ...